论文部分内容阅读
肺动脉高压是一种以肺小动脉血管重构为特征的恶性肺血管疾病,往往由于肺血管阻力进行性升高并最终导致患者右心力衰竭而死亡。5型磷酸二酯酶在肺组织中高表达为5型磷酸二酯酶抑制药治疗肺动脉高压提供了理论基础。伐地那非是一种新型选择性的磷酸二酯酶抑制药,通过减少环鸟苷酸(cGMP)的降解而舒张肺血管平滑肌,降低肺血管阻力。本文通过对伐地那非的药代动力学、伐地那非治疗肺动脉高压的临床研究及其在肺动脉高压危象的应用方面阐述伐地那非治疗肺动脉高压的研究。
Pulmonary hypertension is a type of malignant pulmonary vascular disease characterized by remodeling of pulmonary arterioles and often dies as a result of progressive increases in pulmonary vascular resistance and eventually in patients with right heart failure. Type 5 phosphodiesterase is highly expressed in lung tissue as a type 5 phosphodiesterase inhibitor for the treatment of pulmonary hypertension provides a theoretical basis. Vardenafil is a novel and selective phosphodiesterase inhibitor that relaxes pulmonary vascular smooth muscle and reduces pulmonary vascular resistance by reducing the degradation of cGMP. In this paper, vardenafil pharmacokinetics, vardenafil in the treatment of pulmonary hypertension in the clinical study and its application in the risk of pulmonary hypertension on vardenafil treatment of pulmonary hypertension.